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ABSTRACT 
It is thought that both genetic and epigenetic variation play a role in Alzheimer’s disease 
initiation and progression. With the advent of somatic cell reprogramming into induced 
pluripotent stem cells it is now possible to generate patient derived cells that are able to 
more accurately model and recapitulate disease. Furthermore, by combining this with recent 
advances in (epi)genome editing technologies it is possible to begin to examine the 
functional consequence of previously nominated genetic variants and infer epigenetic 
causality from recently identified epigenetic variants. In this review we explore the role of 
genetic and epigenetic variation in Alzheimer’s disease and how the functional relevance of 
nominated loci can be investigated using induced pluripotent stem cells and (epi)genome 
editing techniques. 
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MAIN BODY OF ARTICLE 
 
Alzheimer’s disease 
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and accounts for 
approximately 60-80% of all dementia cases worldwide [1]. Dementia is estimated to affect 
46.8 million people worldwide, with this set to double every 20 years reaching 131.5 million 
in 2050 [2]. The disease is characterized by the accumulation of amyloid beta (Aβ) plaques, 
intracellular neurofibrillary tangles of hyperphosphorylated tau [3] and loss of synaptic 
connections [4];  taken together these lead to neuronal cell death. This is accompanied by 
cognitive and behavioral changes, such as memory impairments, language disturbance and 
hallucinations. The early cognitive decline in AD can be attributed to the degeneration of 
cholinergic neuronal cells found in the cortical and limbic brain regions such as the 
hippocampus [5] and the basal forebrain [6]. 
 
The deposition of senile plaques and tangles does not occur at random, but follows a distinct 
and characteristic pattern [7-10], starting in the neocortex and then the hippocampus [11], 
whilst other regions, such as the cerebellum, remain relatively unaffected [12]. This specific 
topographical distribution correlates with, and explains, the characteristic symptoms of AD; 
the hippocampus and neocortex are well known for being involved in controlling emotions, 
memory and higher brain function [13, 14]. The cerebellum on the other hand is responsible 
for the coordination, motor and voluntary movements, and there are far fewer aberrations in 
these in AD patients when compared with the prevalence of other symptoms [15]. There is 
already considerable pathology before the disease is diagnosed [16], with the onset of 
symptoms sometimes occurring at least 10 years after Aβ is first deposited [17]. This 
apparent delay in the appearance of symptoms is caused by there being a threshold of 
cholinergic loss before the brain can no longer compensate and ameliorate the deficit [11]. 
Although much progress has been made in understanding the cellular pathology of AD, the 
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treatments currently available only temporarily alleviate some symptoms and do not modify 
the underlying pathology.  
 
Genetic variation associated with AD 
Given the high heritability estimates (~60-80%) for AD based on quantitative genetic studies 
[18], initial etiological studies have focussed on identifying a genetic basis for disease.   
Although some AD cases are caused by autosomal dominant mutations in three genes 
(APP, PSEN1, PSEN2), these account for less than 5% of AD prevalence and are early-
onset, occurring before the age of 65 years. Most AD cases are late-onset (>65 years) and 
sporadic, with no defined etiology. However in recent years, large cohort collections and the 
relatively inexpensive cost of assessing genetic variation through genome-wide association 
studies (GWAS) has allowed the identification of common variants associated with risk of 
developing AD. These studies have demonstrated that late onset Alzheimer’s disease 
(LOAD) is thought to be multifactorial with many different genes and single nucleotide 
polymorphisms (SNPs) being implicated in, and contributing to, disease onset and 
progression [18]. The most robustly associated gene with LOAD is Apolipoprotein E (APOE), 
which encodes a polymorphic glycoprotein that is involved in the transport of cholesterol and 
other lipids [19] alongside neuronal growth [20] and tissue repair [21]. There are three 
isoforms of APOE that all correspond to allelic variation at a single locus, ɛ2, ɛ3 and ɛ4, 
which can be distinguished by cysteine to arginine substitutions at the amino acid positions 
112 and 158 [22]. The ɛ4 variant confers increased risk of developing LOAD, with each 
additional copy of the risk allele lowering the mean age of onset [23]. Whilst APOE ɛ4 
accounts for approximately 20% of genetic risk for developing LOAD it cannot explain all of 
disease incidence, as not everyone who is homozygous for ɛ4 actually develops AD [24]. 
Aside from APOE there are numerous other risk loci (SNPs) that have been implicated in 
AD. The most recent meta-analysis of nearly 75,000 individuals nominated 19 common 
genetic variants, of which 11 were novel disease loci [25] (Table 1). Interestingly, many of 
the GWAS loci that have been nominated for AD can be linked to amyloid processing or 
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inflammation. Whilst risk variants that have been identified from GWAS only confer a 
relatively modest effect size, with odds ratios (ORs) between 0.73 and 1.22 per loci 
investigated [26], it is thought that these could act cumulatively to cause the onset of 
degeneration. Scientists have generated polygenic risk scores (PRS) for AD, which combine 
the effects of many disease-associated SNPs to predict disease risk [27] and recently it has 
been reported that the PRS prediction captures nearly all common genetic risk for AD [28].  
However, another study has demonstrated that collectively common SNPs for AD only 
account for a third of phenotypic variance in AD [29]. Recent efforts to explain the missing 
heritability of AD have used sequencing approaches to identify rare variants, with a larger 
effect size, with SNPs in PLD3, TREM2, TM2D3 and PICALM being nominated in recent 
years [30-34]. 
 
Table 1: Summary table of SNPs associated with AD, which reach genome wide 
significance in Lambert et al, 2013 [25]. Abbreviations: Chr. = Chromosome  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Chr:Position Closest Gene Odds Ratio 
rs6656401 1:207692049 CR1 1.18 
rs6733839 2:127892810 BIN1 1.22 
rs10948363  6:47487762 CD2AP 1.10 
rs11771145 7:143110762 EPHA1 0.90 
rs9331896 8:27467686 CLU 0.86 
rs983392 11:59923508 MS4A6A 0.90 
rs10792832 11:85867875 PICALM 0.87 
rs4147929 19:1063443 ABCA7 1.15 
rs3865444 19:51727962 CD33 0.94 
rs9271192 6:32578530 HLA-DRB5– HLA-DRB1 1.11 
rs28834970 8:27195121 PTK2B 1.10 
rs11218343 11:121435587 SORL1 0.77 
rs10498633 14:92926952 SLC24A4 RIN3 0.91 
rs8093731 18:29088958 DSG2 0.73 
rs35349669 2:234068476 INPP5D 1.08 
rs190982 5:88223420 MEF2C 0.93 
rs2718058 7:37841534 NME8 0.93  
rs1476679 7:100004446 ZCWPW1 0.91 
rs10838725 11:47557871 CELF1 1.08 
rs17125944 14:53400629 FERMT2 1.14 
rs7274581 20:55018260 CASS4 0.88 
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Despite the fact that GWAS and sequencing efforts have been successful in identifying novel 
genes involved in AD, the majority of SNPs lie outside of coding regions of the genome. 
These variants are thus unlikely to have direct structural or functional effects on their gene’s 
protein product, and are more likely to affect gene regulation at other loci. By integrating 
genetic variation with transcriptomic measurements in the same samples, for example from 
microarray or RNA sequencing experiments, it is possible to correlate disease associated 
genetic variants with changes in gene expression to identify expression quantitative trait loci 
(eQTLs). Such disease-associated eQTLs can occur both within the same gene (in cis) or 
distally within another gene (in trans). Recent research indicates that SNPs may change 
expression by initially altering the binding ability of one ‘pioneering’ transcription factor (TF), 
which then recruits other TFs. This was shown to occur at a CTCF motif, which if disrupted 
affects the binding of five different TFs [35]. However, if there are two or more variants in 
perfect linkage disequilibrium (LD) with one another, the non-random association of loci at 
different genomic locations, then it is not possible to distinguish which variant is acting as the 
eQTL. To further complicate matters, many eQTLs act in a cell type specific manner [36]. 
This is particularly relevant when studying heterogeneous tissues such as the brain or blood 
or in a disease such as AD, when cellular abundance is known to be altered [37, 38]. In the 
context of AD, one recent study demonstrated an enrichment for monocyte-specific eQTLs 
at disease-associated loci, suggesting a role of the innate immune system in AD pathology 
[39]. In support of this, Karch et al, tested whether GWAS LOAD SNPs act as cis-eQTLs for 
LOAD GWAS genes [40]. They were able to show the AD SNP rs1476679 in ZCWPW1, was 
significantly associated with the expression of PILRB and GATS in most brain regions, 
including the hippocampus. Interestingly, PILRB acts as a binding partner for TYROBP, both 
of which can be found on microglia [41]. The expression of TYROBP is restricted to cells of 
the immune system such as microglia, and has been shown to be up-regulated in the brains 
of patients with LOAD. In a recent gene-regulatory network analysis TYROBP was shown to 
be a key causal regulator of a microglial/immune module highlighted as the module most 
associated with pathophysiology of LOAD. This microglia/immune module was also shown to 
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contain a number of AD GWAS risk loci, such as CD33, MS4A4A and MS4A6A [39]. 
Furthermore, TREM2, which has been recently nominated from sequencing studies, is 
known to interact and signal through TRYOBP [39]. Taken together many network level 
analyses have highlighted a role for microglia and neuroinflammation in AD risk [39, 40, 42, 
43].  
 
A role for epigenomic dysfunction in AD? 
Recently, increased understanding about the functional complexity of the genome has led to 
growing recognition about the likely role of non-sequence-based “epigenetic” variation in AD 
[44]. Epigenetic processes mediate the reversible regulation of gene expression, occurring 
independently of DNA sequence, acting principally through chemical modifications to DNA 
and nucleosomal histone proteins (Figure 1). The most widely studied epigenetic 
modification in human studies is that of DNA methylation, given it is the most stable and 
longest lasting change.  
 
In general, in vitro studies have suggested that there is a trend towards global DNA 
hypomethylation in AD. For example, one study demonstrated global hypomethylation in a 
glioblastoma cell line with the APPSWE mutation, which occurs in familial AD [45]. Likewise, it 
was shown that there are lower DNA methylation levels in brain microvascular endothelial 
cells that were exposed to high levels of synthetic Aβ1-40 [46]. However, in contrast to this a 
more recent study using neuroblastoma cells exposed to synthetic Aβ1-40  showed no 
significant change in DNA methylation levels [47]. In the context of human post-mortem brain 
samples there are also some conflicting results; contrasting studies have shown decreased 
levels of global DNA methylation in AD-associated brain regions such as the entorhinal 
cortex [48] and hippocampus [49], whilst others report no change [50, 51] or even increased 
levels in the frontal cortex [52] and hippocampus [53]. 
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Figure 1. Diagram to illustrate the different epigenetic mechanisms that have been 
identified. (A) Regulation of chromatic structure through post-translational modifications 
to histone proteins. This can include: acetylation, methylation, SUMOylation, 
ubiquitylation, citrullination and ADP-ribosylation. (B) Addition of chemical tags to DNA to 
the 5’ end of a cytosine nucleotide. This creates 5-methylcytosine (5mC – the most 
commonly studied epigenetic mark), 5-hydroxymethycytosine (5hmC), 5-carboxylcytosine 
(5caC) and 5-formylcytosine (5fC). (C) Small RNA molecules, such as microRNA can 
also affect gene expression either through degrading mRNA or altering protein 
translation. 
 
 In recent years, advances in genomic technology have allowed the first genome-scale 
studies of DNA methylation in AD [54, 55]. To date, all published studies have utilized the 
Illumina Infinium 450K Methylation Beadarray (450K array) to examine DNA methylation 
changes at >485,000 loci in post-mortem brain samples. Although these epigenome-wide 
association studies (EWAS) have been performed on independent sample cohorts, in a 
range of anatomically distinct cortical brain regions, a number of consistently differentially 
methylated genes have been identified [56]. Most notably one such gene to be robustly 
hypermethylated in AD cortex is Ankyrin1 (ANK1) [54, 55]. Interestingly, disease-associated 
ANK1 hypermethylation has been observed in a tissue-specific manner, with brain regions 
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affected by AD pathology (entorhinal cortex, superior temporal gyrus and prefrontal cortex) 
showing significant hypermethylation, whilst the cerebellum, a region largely unaffected by 
pathology, and pre-mortem blood show no disease-associated changes. The majority of 
genes identified by EWAS are distinct from those nominated in GWAS with the exception of 
BIN1. However, despite different genes being identified with the two approaches many of 
these do reside in common pathways [57]. Since the publication of the initial EWAS, there 
have been additional studies identifying additional differentially methylated genes in AD, 
including CRTC1 [58], APOE  [59] and TREM2 [60]. 
 
To date the majority of AD EWAS have focussed on DNA methylation, with histone 
modifications considerably less well studied. However, one study has shown that the histone 
deacetylase (HDAC) inhibitor, sodium butyrate, can improve cognitive function, synaptic 
density and plasticity in mouse models with inducible overexpression of p25 protein [61]. 
P25 has been shown to be linked to numerous features of AD such as amyloid and tau 
pathology alongside memory loss and neurodegeneration [62-64]. These findings have been 
corroborated by another, who also demonstrated improved memory function after treatment 
with sodium butyrate in transgenic APPPS1-21 mice [65]. Furthermore, memory 
improvements were seen even when it was administered at the latest stages of amyloid 
pathology and were associated with increased expression of genes implicated in associative 
learning. Other studies have also shown HDACs to have therapeutic utility, such as 
Depakote [66], phenylbutryic acid [67] and trichostatin A [68]. Whilst these studies are 
encouraging and show the potential utility of HDACs as therapeutic agents there are, 
however, a couple of considerations with this approach. First, most models, including the 
ones we describe, are models of familial AD, which use small numbers of animals and, as 
such, results should not be over interpreted. Alongside this, these studies use pan-HDAC 
inhibitors, which are all known to affect multiple HDACs. Whilst it is useful to know that there 
may be some involvement of histone modifications or HDACs in AD initiation or progression, 
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these studies do not highlight specifically which ones are implicated. In order to address this, 
a number of groups have crossed APPPS1-21 mice with those lacking certain HDACs. 
APPPS1-21 mice that lack HDAC5 show exaggerated memory impairment [69], whilst those 
lacking HDAC6 have improved memory, but this is achieved without changing amyloid 
deposition [70]. Another HDAC that could have potential as a therapeutic target is HDAC2, 
as mice with reduced HDAC2 show increased memory and synaptic plasticity [71]. 
Therefore, it appears that only specific HDACs show promise as potential drug targets. 
When using certain HDACs it is important to be aware that they can also affect DNA 
methylation. For instance it has been shown that Depakote can cause extensive DNA 
methylation changes including demethylation changes at specific genes such as MMP2, 
MAGEB2 and WIF1, which have been implicated in tumour growth and metastasis [72]. This 
study supports the concept that various epigenetic marks are in a dynamic relationship with 
one another and that you cannot necessarily target one without affecting another. Finally, as 
with any potential drug that is tested on model systems, such as mice, it is important to 
remember that these rarely translate effectively into humans. One good example of this 
comes from studies which demonstrated the utility of anti-amyloid antibodies [73]. In these 
APP-transgenic mice, just one injection of m266, an anti-APP mouse antibody, was able to 
reverse cognitive deficits without reducing amyloid plaque burden [73]. However, when taken 
to phase three clinical trials, the human antibody, Solanezumab, did not reduce cognitive 
decline in those with mild dementia due to AD [74].  
 
Induced pluripotent stem cells: new models for late-onset Alzheimer’s disease? 
To fully understand and elucidate the mechanisms of disease etiology, extensive modelling 
must take place. Traditionally, this has been achieved by a number of methods, including 
both animal (murine) models and primary patient cell lines. Whilst both of these approaches 
have their own merits, they can prove inconvenient and do not completely and accurately 
reflect human disease. At present, the AD research field has had a heavy focus on disease 
modelling through the use of transgenic mouse models [75], as there is a well-developed 
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understanding of genetic manipulation techniques in this organism. Furthermore, mice are 
more phylo-genetically related to humans than other simpler model organisms such as 
drosophila melanogaster and caenorhabditis elegans, although these do allow for more 
experimental control than mice. Due to the close relation of mice and humans they also have 
good utility for studying familial AD, through the use of transgenic mice containing mutations 
in the APP and PSEN genes. This has led to advances in our understanding of multiple 
aspects of AD, in particular amyloid pathology and the differential effects of the various Aβ 
peptides. However, despite the extensive use of these transgenic models to study AD, they 
do not accurately recapitulate AD, as the mice do not display overt neurodegeneration [76-
78] or have amyloid plaques [79]. Whilst proven useful for modelling autosomal disease, 
such as familial AD, the mouse models do not have extensive utility for studying sporadic 
AD, which has both polygenic and environmental components. Even if it were possible to 
model the genetics of sporadic AD in transgenic mice the effect sizes of each associated 
variant would be small and therefore difficult to determine phenotypic outcome. However, 
there have been murine studies that have targeted replacement of the endogenous murine 
Apoe gene with human APOE-ε4. These mice demonstrated reduced spatial learning and a 
reduction in dendritic spine density in the medial entorhinal cortex [80]. In another study 
where APOE (both ε3/ε3 and ε4/ε4) mice were crossed with mice containing a mutant 
human form of APP, the APOE-ε4xAPP mice displayed significantly worse spatial memory 
performance than their APOE-ε3xAPP counterparts, but this was also associated with insulin 
dysfunction [81].  
 
A more promising avenue for modelling SNPs in complex diseases, such as sporadic AD, is 
through the use of stem cell technology. Embryonic stem cells (ESCs), which are derived 
from the inner cell mass of an embryo (blastocyst), have the ability to differentiate into any 
cell in the body [82]. Due to their inherent plasticity, and as genomic variation can be 
assessed relatively inexpensively through PCR, microarray, or sequencing technology, there 
is the potential that they could be used to study the effect of disease-associated SNPs on 
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the functionality of specific cell types. However, whilst useful, the ethical issues implicated 
with using embryo derived ESCs are numerous. Recent advances in stem cell technology 
have allowed the production of stem cells derived from adult tissue, such as blood, urine and 
keratinocytes [83]. These induced pluripotent stem cells (iPSCs) have almost identical 
characteristics to ESCs: they share the same morphology, can differentiate into any cell type 
in the body, have unlimited growth and have the same expression pattern of genes [84]; 
potentially making them a very powerful tool in research.  
 
There are, however, a number of caveats when utilizing iPSCs to model complex diseases 
that must be considered. Associated with inducing pluripotency are the global cellular 
epigenetic changes that allow the cells to alter gene expression in order for them to be 
functionally identical to ESCs. Despite being functionally identical, several groups report that 
iPSCs have different DNA methylation profiles and gene expression patterns to ESCs [85-
88]. Some groups attribute this variation due to an ‘epigenetic memory’ where iPSCs show 
residual DNA methylation patterns that are typical of the tissue they originate from [89]. 
These differentially methylated regions (DMRs) were shown to affect the differentiation 
potential of the newly formed iPSCs. For example, iPSCs derived from neural and fibroblast 
progenitors maintained DNA methylation marks at sites associated with haematopoietic 
lineages, which decreased the potential for these iPSCs to form blood cells. Subsequently, it 
is possible to reverse these restricting methyl marks by increasing the cells passage number 
or treatment with chromatin modifying compounds [89]. This treatment is associated with a 
decrease in DNA methylation at haematopoietic loci and therefore an increase in blood cell 
fate potential. Therefore, although it would appear that this epigenetic memory can affect the 
differentiation potential of cells initially, this effect is actually only transient. It has also been 
observed that certain subsets of cells can become stuck in a partially reprogrammed state. 
This is due to inefficient DNA demethylation at certain sites or the incomplete repression of 
TFs [90]. Despite this, these aberrations can be rectified using RNA inhibition of TFs or 
treatment with DNA methylase inhibitors. Another potential source of epigenetic variation 
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between ESCs and iPSCs is the microenvironment in which the iPSCs have been 
generated. Cooper and Newman have demonstrated that there is some correlation between 
cells’ gene expression patterns and the laboratory the cell lines are derived from [91, 92]. 
This demonstrates that the environment can affect the epigenome and therefore 
downstream gene expression of cell lines. To fully assess the differences in the epigenomes 
between iPSCs and ESCs, Lister et al, utilized a shotgun bisulphite sequencing technique 
(MethylC-seq) to look at the whole-genome DNA methylome at single base-pair resolution 
[93]. This demonstrated that, overall, ESCs and iPSCs are similar, but that there are some 
inherent differences between their DNA methylomes. The reprogramming of somatic cells 
generated hundreds of DMRs that could be attributed to both memory from the somatic cell 
and iPSC specific DNA methylation patterns that are susceptible during the reprogramming 
process as many DMRs were consistent across independent iPSC lines [86]. All of these 
studies demonstrate that there are fundamental differences in both the epigenome and gene 
expression patterns of ESCs and iPSCs. However, there are ways to rectify some of these 
differences meaning that iPSCs still have utility as disease models, although the differences 
must be taken into account when interpreting results. 
 
Since the introduction of iPSC technology there have been increasingly more studies 
utilizing iPSCs for disease modeling and small molecule testing as, theoretically, iPSCs are 
an exact genetic match of the patient they are derived from. To accurately model AD using 
iPSCs, the generation of specific neuronal populations are usually necessary, particularly 
iPSC derived cortical and cholinergic neurons. Generating these requires certain factors, 
including SB431542 and LDN-193189 [94], which act as inhibitors of TGF-β I and BMP type 
I receptors respectively. This inhibition prevents SMAD phosphorylation, supressing cellular 
renewal and promoting cortical differentiation [95, 96].  A good iPSC model of AD would not 
only be the correct cell type of interest, but also show the neuropathological features and 
characteristics of the disease. There have been several studies that have reported that 
iPSCs show certain disease features [97-100]. More specifically, in AD iPSCs have also 
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been used to show Aβ-induced synaptotoxicity [101]. In this study, Nieweg et al 
demonstrated not only that Aβ altered AMPA receptors post-synaptically and impaired 
axonal vesicle clustering, but also increased the phosphorylation status of tau, another key 
characteristic hallmark of AD. Alongside aberrations in tau phosphorylation, degeneration of 
cortical neurons is also a very prominent clinical feature of AD, and it is believed that this 
causes the onset of symptoms. Therefore, to truly understand AD as a disease, being able 
to recapitulate this neuronal cell death is vital. One recent study has shown that iPSC 
derived basal forebrain cholinergic neurons (BCFNs) heterozygous for APOE (ε3/ε4) are 
more susceptible to glutamate mediated cell death, whilst also showing an increased 
Aβ42/Aβ40 ratio when compared to BCFNs generated from healthy age matched control 
patients [102].  
 
One of the major utilities for using iPSCs to study AD is the ability to examine the effects of 
genetic variants with a relatively small effect size on phenotype. One study which takes 
advantage of this has demonstrated that iPSC-derived neurons carrying genetic variants in 
SORL1, which increase LOAD risk, have reduced response to BDNF treatment. This not 
only manifests at the level of SORL1 expression but also impacts APP processing [103]. 
Furthermore, given that AD has a polygenic component, it is also possible to assess the 
effect of different combinations of disease-associated SNPs. As it is possible to use iPSCs to 
generate patient specific neuronal cells, there is the potential to generate libraries of cells 
with varying combinations of LOAD-associated SNPs and therefore different susceptibilities 
to disease. Interestingly, two studies have demonstrated this variability in susceptibility using 
LOAD iPSC-derived neurons [104, 105]. In the first, undertaken by Israel et al, they found 
that neurons from one patient, but not from another, showed AD-associated phenotypes. 
This included altered levels of secreted Aβ1-40, higher aGSK3 levels and had significantly 
increased p-tau/total tau [104]. The second study, conducted by Kondo et al, showed 
differential intracellular Aβ oligomer accumulation, inducing endoplasmic reticulum  and 
oxidative stress [105]. Taken together these studies show how different genetic backgrounds 
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can alter disease initiation and progression as well as the complex genetic interplay there is 
in LOAD. However, being able to investigate the effects of different polygenic risk scores on 
living and developing neuronal populations will provide more valuable insight into the role 
genetic variants play in terms of physiological/cellular aberrations and disease progression in 
LOAD. Importantly, data that is generated through the usage of iPSCs can therefore be 
compared and contrasted with data collected from molecular studies in human post-mortem 
tissue to potentially elucidate the disease-specific effects.  
 
Using genetic editing to elucidate the functional consequence of disease-associated 
variation 
Using iPSCs and recent advances in (epi)genetic editing technology it is becoming possible 
to start teasing apart the underlying mechanisms that may be driving AD pathogenesis. 
Clustered regularly interspersed short palindromic repeats (CRISPR) uses RNA guided 
Cas9 nucleases to introduce DNA breaks which can be repaired through homologous 
recombination, indel mutations or with a vector carrying a desired mutation [106]. CRIPSR 
can be used provided that the sequence of interest is unique compared to the rest of the 
genome and is upstream of a protospacer adjacent motif (PAM) sequence. The PAM 
sequence is typically three to five nucleotides long and serves as a binding region for the 
Cas9 to bind. Unfortunately, this is a requirement of the method and can be technically 
challenging. Despite the PAM sequences being relatively common throughout the human 
genome they can often be in the incorrect location relative to the sequence of interest and 
can make modifying the gene difficult. Furthermore, if the target locus has high homology to 
another region in the genome then there is the potential for off-target effects resulting in 
inadvertent mutations [107, 108]. 
 
The main advantage of the CRISPR-Cas9 system is that you can create isogenic control 
lines that only show genetic variation at your disease-specific loci. One recent example of 
this in the AD field comes from Pires et al, who successfully corrected the A79V PSEN1 
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mutation in a patient AD iPSC cell line [109]. These types of control lines are extremely 
beneficial for studying disease-associated genetic variation, as they enable the minimization 
of genetic variability as both disease and control lines have the same genetic background. 
Such isogenic lines have been recently used to study familial AD [105, 110, 111]. One study 
has shown iPSCs harbouring the APPSWE and PSEN1 M146V mutations have increased 
total Aβ production, and up to a threefold increase in the Aβ42/Aβ40 ratio when compared to 
their isogenic controls. These changes have been shown to correlate to neuronal identity, 
maturity and mutation load [112].  
 
Whilst it proves relatively simple to use this technique to study the effects of causative 
mutations, such as those in familial AD, other genetic variants like SNPs associated with 
sporadic AD are more problematic to model. This is due to the fact that they may only be 
relevant to diseases such as AD in specific combinations. As an extension to the CRISPR 
system, it is possible to alter multiple loci using CRISPR-multiplexing [113]. In this system 
multiple guide RNAs are assembled into the same vector and transfected into the cells 
allowing the targeting of multiple loci. This tool will undoubtedly prove incredibly useful for 
LOAD research as it will allow researchers to modify up to seven loci. By modifying multiple 
disease-associated SNPs, one could investigate the effects of various combinations on cell 
physiology, protein expression and aggregation. This approach would work very well for the 
LOAD risk SNPs BIN1, CLU and PICALM, for example, as these have all been shown to 
interact with Aβ/tau [114-117]. Therefore by altering these specific SNPs one could 
investigate how tau and Aβ pathology changes over time. Another interesting point is that 
this methodology would allow one to investigate the interaction between disease-associated 
SNPs with reported relationships, for example PICALM and the APOE ε4 allele. In a 
previous study of familial AD patients, a homozygous PICALM genotype (rs3851179) was 
shown to modulate prefrontal cortex volume and cognitive impairment in carriers of the 
APOE ε4 allele [118]. As both proteins are involved in the same Aβ clearance pathway [119, 
120], it is thought that alterations in the endocytic functions of PICALM may synergistically 
 17 
 
affect APOE ε4. This could mean there is a higher likelihood of Aβ remaining in the brain 
and therefore increasing plaque formation. 
 
Establishing Causality  
An important step for research is to establish whether disease-associated variation is 
causing disease. This is simpler to test when examining genetic variation, as we know that 
the SNP has been present in an individual throughout their life course, prior to disease 
onset. However, when investigating the functional effects of disease-associated epigenetic 
variation, the relationship is less clear, and it is difficult to determine whether epigenetic 
changes are a cause, or a consequence of, the disease process. Whilst previous post-
mortem brain studies have provided valuable physiologically relevant information about 
epigenetic changes occurring at later disease stages it is difficult to establish if those 
alterations actually initiated disease, therefore making it problematic to infer causality.  In 
any disease it is critical to be certain of what is causing disease, but particularly so in AD. 
First because this is crucial for the design of effective drug therapies to combat disease, and 
second, because AD neuropathology generally occurs at least 10 years before symptomatic 
onset, it is important to understand the root cause(s) to be able to monitor and diagnose the 
disease in its very earliest stages. iPSCs have real utility for determining whether 
associations identified in EWAS analyses could represent a secondary effect of disease, or 
could be driving disease progression. Using a modified version of the CRISPR-Cas9 
technology it has become possible to alter DNA methylation at specific loci. By fusing the 
Cas9 protein with the enzymatic domains of TET1 or DNMT3A it is possible to remove, or 
add methyl groups to DNA respectively [121]. This method builds on previous work [122, 
123] where Tet1 and Dnmt3a were fused to TALE proteins to achieve the same effect. By 
being able to manipulate the epigenetic landscape of cells, particularly at loci associated with 
disease it will enable researchers to establish whether disease-associated epigenetic 
variation is causative. These techniques have already been utilized in diseases such as 
cancer [124, 125], but to our knowledge have not yet been reported in AD research. The 
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epigenetic status of genes such as ANK1 which have robust changes in AD would be an 
excellent initial target for this new methodology. It has the potential to reveal whether the 
DNA methylation changes seen are truly causative and precede disease initiation, or 
whether they are a consequence of progression. Even if it is the latter and it is found that 
these alterations do not cause disease, but occur in the earliest stages of the disease, they 
could potentially be used as a biomarker for diagnosis prior to symptomatic onset. Alongside 
this, such changes also tell us something about the disease process and its progression. 
Given that recent studies have demonstrated robust epigenetic alterations in AD, iPSCs 
could become a valuable tool in which these studies could be taken further. However, to 
undertake epigenetic studies in these cells it will be very important to fully understand the 
epigenetic landscape of the iPSCs themselves, both throughout differentiation and at 
maturity.  
 
Current challenges to Progress 
Whilst it is possible to create disease relevant cells using iPSCs, as with any model, iPSCs 
also have their limitations. A large concern when using iPSC-derived neurons to model 
disease is that the resulting neurons represent an immature and fetal population [126-129]. 
This is of particular concern when studying diseases of aging, such as LOAD. However, 
efforts are being made to overcome this particular issue. For example by expressing a 
mutant form of LMNA, which is known to cause premature aging. By expressing progerin in 
the iPSC-derived dopaminergic neurons it was possible to create phenotypes that were 
resultant of both the induced aging and genetic susceptibility [130]. The aged Parkinson’s 
disease neurons had marked dendrite neurodegeneration, reduced tyrosine-hydroxylase 
expression and displayed epigenetic markers of aging that were not present in the control 
populations. Another study directly reprogrammed fibroblasts into neurons, skipping iPSC 
pluripotency stages, in an attempt to overcome iPSC immaturity [131]. As this protocol does 
not induce pluripotency the inducible neurons (iNs) display both age-related epigenetic and 
transcriptomic signatures showing age-associated decreases in RanBP17, a nuclear 
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transport receptor. Whilst these neurons would prove useful for studying diseases of aged 
cells, such as AD, it is difficult to make large amounts of primary material as these cells 
cannot be propagated, unlike the iPSC cells.   
 
FUTURE PERSEPECTIVE 
Since the pioneering work by Takahashi and Yamanaka in 2006, the use of iPSCs has been 
able to significantly advance complex disease research. They have enabled researchers to 
more accurately recapitulate disease phenotypes in a cell culture system. Whilst iPSCs are 
far from being used therapeutically, they have proven useful for investigating the molecular 
and genetic underpinnings of LOAD. Once there have been more extensive investigations 
into the effects of SNP burden and their molecular targets, iPSCs can be used to test the 
effectiveness of new therapeutic interventions. Although at present iPSC generation and 
differentiation are costly and time consuming, differentiation protocols are quickening, and 
the use of an individual’s own iPSCs to select their appropriate treatment would be a first 
step towards personalized medicine, potentially improving the patient’s life.  
 
Whilst it is still unknown whether the global epigenetic changes that occur during iPSC 
generation affect the end epitype of cells, there is still promise that these cells could be used 
to study the epigenetics of complex diseases. If epigenetic aberrations do prove to be an 
issue, then these will have to be taken into account during experimental design and analysis. 
However, before identified changes can be targeted for therapeutic intervention it will be 
important to determine whether they are causal; with the recent advances in genetic and 
epigenetic editing technology this will soon be possible. Finally, while there are many 
questions that still remain unanswered and many challenges ahead when addressing these, 
with the correct model and methodologies these will hopefully be overcome. 
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EXECUTIVE SUMMARY 
Alzheimer’s disease (AD) 
• Most prevalent neurodegenerative disorder causing 60-80% of dementia cases 
worldwide 
• Characterised by extracellular depositions of amyloid beta (Aβ) protein and 
intracellular neurofibrillary tangles of paired helical filaments of tau 
Genetic variation associated with AD 
• Through the use of genome wide association studies (GWAS) a number of single 
nucleotide polymorphisms (SNPs) have been associated with late onset AD 
• Many GWAS loci implicated in disease have been linked to amyloid processing and 
inflammation 
A role for epigenomic dysfunction in AD? 
• Recent epigenome wide association studies (EWAS) have identified a number of loci 
that are differentially methylated in disease 
• The majority of genes identified by EWAS are distinct from those nominated in 
GWAS with the exception of BIN1.  
Induced pluripotent stem cells (iPSCs): new models for late-onset AD? 
• Through somatic cell reprogramming it is possible to generate induced pluripotent 
stem cell (iPSC) derived neuronal cells 
• These iPSC-derived neuronal cells have been shown to reflect some disease 
features 
• iPSC-derived neuronal cells can be used to assess the effect of polygenic risk on 
physiological/cellular changes and disease progression  
Using genetic editing to elucidate the functional consequence of disease-associated 
variation 
• Clustered regularly interspersed short palindromic repeats (CRISPR) uses RNA 
guided Cas9 nucleases to introduce modifications in the genome 
 21 
 
• CRISPR-multiplexing can be used to edit multiple loci within the genome 
Establishing Causality  
• iPSC models have utility in determining whether loci identified from GWAS and 
EWAS are causative in the disease process 
• Using CRISPR the epigenetic landscape of cells can be altered to establish whether 
DNA methylation changes associated with disease are causative 
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